Thomas Lee
CEO @ Galileo
New York, United States
Thomas Lee is a seed investor at Galileo in New York focused on Health Care and Medical. Tom X Lee is the CEO of Galileo. Took up BS, Biology at Yale University.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Thomas Lee invests in
Stages Thomas Lee invests in
Countries Thomas Lee invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $3M–$9.5M
- Series A
- $10M–$22M
- Series B
- $26M–$40M
Investment Focus
Industry
- Health Care 16 (84%)
- Medical 8 (42%)
- Artificial Intelligence 6 (32%)
- Wellness 4 (21%)
- Personal Health 3 (16%)
Stage
- Seed 8 (42%)
- Series A 6 (32%)
- Series B 3 (16%)
- Pre-Seed 2 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Systole Health
|
Systole Health enables women to take immediate action to improve their health, prevent heart disease, and regain their well-being. Systole Health's mission is to transform women's heart health care by offering prompt, transformative assistance. | $2M / Pre-Seed / Jan 27, 2025 | |
Allara
|
Allara is a healthcare program that allows patients to access expert, specialty care through virtual appointments. Allara offers a medical provider and a registered dietitian for polycystic ovary syndrome. They provide holistic care, diagnostic testing, prescriptions, video appointments with a medical provider, dietary and lifestyle changes,nutrition counseling, and medication. | $26M / Series B / Jan 24, 2025 | |
Parakeet Health
|
Parakeet Health is a AI contact center agent for healthcare practices. | $3M / Seed / Oct 15, 2024 | |
|
Allara
|
Allara is a healthcare program that allows patients to access expert, specialty care through virtual appointments. Allara offers a medical provider and a registered dietitian for polycystic ovary syndrome. They provide holistic care, diagnostic testing, prescriptions, video appointments with a medical provider, dietary and lifestyle changes,nutrition counseling, and medication. | $10M / Series A / Oct 18, 2023 | |
Glass Health
|
Glass Health empowers clinicians with a platform for AI-assisted diagnosis and clinical decision-making | $5M / Seed / Sep 11, 2023 | |
Oula Health
|
Oula is redesigning maternity care from the ground up. Its modern maternity center combines the best of obstetrics and midwifery care to deliver a more evidence-based and personalized pregnancy experience. From its collaborative medical team, welcoming clinic, and remote care platform, we are setting a new standard for pregnancy that unifies modernmedicine and human intuition.The company was founded in 2019 and is headquartered in Brooklyn, New York. | $19.1M / Series A / Jan 12, 2023 | |
Nava
|
Nava is a new kind of benefits brokerage on a mission to bring high-quality, affordable healthcare to employers and their employees. It offers healthcare tools, year-round employee advocacy, and ongoing measurement to monitor and recommend healthcare plans, thus enabling clients to provide the required benefits to their employees while loweringoverall plan cost. | $40M / Series B / Jun 08, 2022 | |
Topography Health
|
Topography Health is creating new opportunities in clinical research. | $21.5M / Series A / Jan 19, 2022 | |
Commons Clinic
|
Commons Clinic is a multi-specialty clinic that provides healthcare treatment to patients. The company's clinic offers comprehensive specialty and surgical care programs for pain, orthopedics, women's health, and men's health, enabling patients to avail improved and efficient medical care.The company was founded in 2021 and isbased in Austin, Texas. | $6M / Seed / Sep 07, 2021 | |
Centaur Labs
|
Centaur offers a platform and services for expert data annotation. We provide unmatched accuracy and scale by harnessing the collective intelligence of a global network of tens of thousands of students and professionals who compete with each other to be the best data annotator. | $15M / Series A / Aug 17, 2021 | |
| See all 19 investments → | |||
Co-Investors
About Galileo
Galileo provides high-touch, data-driven, multi-specialty, longitudinal care to a diverse and complex patient population—over the phone, at home, and everywhere in between. Regional and national health plans, employers, and Fortune 500 companies all regard Galileo as the leading solution for improving population health. It aims to use that talentand scientific thinking to transform society by solving the most difficult healthcare problems while also bringing patients and providers closer together.
Galileo Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Caruso
Head of Insights
|
|||
Priya Kumar
Director of Health Plan Implementation & Engagement
|
|||
Ajay Haryani
Clinical Systems Director
|
|||
|
Thomas Lee
CEO
|
|||
Tom X Lee
CEO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Thomas Lee invest in?
Thomas Lee invests primarily in Health Care, Medical and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Thomas Lee's check size?
Thomas Lee typically joins rounds of $3M–$9.5M at Seed, $10M–$22M at Series A and $26M–$40M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Thomas Lee participates in.
How do I contact Thomas Lee?
Public channels for Thomas Lee include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Thomas Lee last invest?
The most recent investment recorded for Thomas Lee closed in Jan 2025. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
